134 related articles for article (PubMed ID: 17949692)
1. The pharmacogenetics of major depression: past, present, and future.
Laje G; McMahon FJ
Biol Psychiatry; 2007 Dec; 62(11):1205-7. PubMed ID: 17949692
[No Abstract] [Full Text] [Related]
2. No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression.
Serretti A; Chiesa A; Calati R; Massat I; Linotte S; Kasper S; Lecrubier Y; Fink M; Antonijevic I; Forray C; Snyder L; Bollen J; Zohar J; De Ronchi D; Souery D; Mendlewicz J
Psychiatry Res; 2011 Jun; 188(1):166-9. PubMed ID: 21168919
[TBL] [Abstract][Full Text] [Related]
3. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder.
Houston JP; Kohler J; Ostbye KM; Heinloth A; Perlis RH
Psychiatry Res; 2011 Oct; 189(3):475-7. PubMed ID: 21788083
[TBL] [Abstract][Full Text] [Related]
4. Genetic studies of drug response and side effects in the STAR*D study, part 1.
Garriock HA; Hamilton SP
J Clin Psychiatry; 2009 Aug; 70(8):1186-7. PubMed ID: 19758527
[No Abstract] [Full Text] [Related]
5. Genetic studies of drug response and side effects in the STAR*D study, part 2.
Garriock HA; Hamilton SP
J Clin Psychiatry; 2009 Sep; 70(9):1323-5. PubMed ID: 19818256
[No Abstract] [Full Text] [Related]
6. Single nucleotide polymorphism in the drug transporter gene ABCB1 in treatment-resistant depression: clinical practice.
Rosenhagen MC; Uhr M
J Clin Psychopharmacol; 2010 Apr; 30(2):209-11. PubMed ID: 20520302
[No Abstract] [Full Text] [Related]
7. Genome-wide association studies in pharmacogenomics of antidepressants.
Lin E; Lane HY
Pharmacogenomics; 2015; 16(5):555-66. PubMed ID: 25916525
[TBL] [Abstract][Full Text] [Related]
8. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
Tsai SJ; Hong CJ; Liou YJ; Chen TJ; Chen ML; Hou SJ; Yen FC; Yu YW
Psychiatry Res; 2009 Sep; 169(2):113-7. PubMed ID: 19700204
[TBL] [Abstract][Full Text] [Related]
9. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
[TBL] [Abstract][Full Text] [Related]
10. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder.
Chi MH; Chang HH; Lee SY; Lee IH; Gean PW; Yang YK; Lu RB; Chen PS
J Affect Disord; 2010 Nov; 126(3):430-5. PubMed ID: 20674983
[TBL] [Abstract][Full Text] [Related]
11. Progress and prospects in pharmacogenetics of antidepressant drugs.
Fabbri C; Crisafulli C; Calabrò M; Spina E; Serretti A
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1157-68. PubMed ID: 27310483
[TBL] [Abstract][Full Text] [Related]
12. Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population.
Yang Z; Ma X; Wang Y; Wang J; Xiang B; Wu J; Deng W; Li M; Wang Q; Li T
Gen Hosp Psychiatry; 2012; 34(5):571-7. PubMed ID: 22795047
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant pharmacogenetics.
Singh AB; Bousman CA; Ng C; Berk M
Curr Opin Psychiatry; 2014 Jan; 27(1):43-51. PubMed ID: 24270480
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder.
Houston JP; Zou W; Aris V; Fijal B; Chen P; Heinloth AN; Martinez J
Psychiatry Res; 2012 Nov; 200(1):63-5. PubMed ID: 22727709
[TBL] [Abstract][Full Text] [Related]
15. Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder.
Ahmed AT; Weinshilboum R; Frye MA
Clin Pharmacol Ther; 2018 May; 103(5):767-769. PubMed ID: 29388201
[TBL] [Abstract][Full Text] [Related]
16. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.
Noro M; Antonijevic I; Forray C; Kasper S; Kocabas NA; Lecrubier Y; Linotte S; Mendlewicz J; Montgomery S; Snyder L; Souery D; Verbanck P; Zohar J; Massat I
Int Clin Psychopharmacol; 2010 Jul; 25(4):228-31. PubMed ID: 20453658
[TBL] [Abstract][Full Text] [Related]
17. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression.
Serretti A; Chiesa A; Calati R; Massat I; Linotte S; Kasper S; Lecrubier Y; Antonijevic I; Forray C; Snyder L; Bollen J; Zohar J; De Ronchi D; Souery D; Mendlewicz J
J Affect Disord; 2011 Jan; 128(1-2):56-63. PubMed ID: 20643483
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder.
Weizman S; Gonda X; Dome P; Faludi G
Neuropsychopharmacol Hung; 2012 Jun; 14(2):87-101. PubMed ID: 22710850
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of antidepressant treatment effects.
Licinio J; Wong ML
Dialogues Clin Neurosci; 2011; 13(1):63-71. PubMed ID: 21485747
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics and major depressive disorder: time to take a stance?
Boivin NR; Jusufi H
Pharmacogenet Genomics; 2024 Apr; 34(3):88-89. PubMed ID: 38179699
[No Abstract] [Full Text] [Related]
[Next] [New Search]
